You are here: vision-research.eu » News » Newsdetails:

New findings show promise for treatment of Graves' disease and other ocular disorders

A new class of therapies may be on the horizon for thyroid eye disease (TED) and other destructive scarring conditions.

At least 50% of patients with Graves' disease, an autoimmune disease that primarily attacks the thyroid gland, develop eye problems including inflammation, discomfort, scarring, and bulging eyes. Abnormal over-production and activation of collagen-producing myofibroblasts underlie many of these conditions. A new study published in The American Journal of Pathology found that activation of the aryl hydrocarbon receptor (AHR) pathway by its ligands blocks collagen production and myofibroblast proliferation in TED.